Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

With AJANTPHARM's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 0.000000
forwardPE 30.119717
debtToEquity 5.698000
earningsGrowth 0.179000
revenueGrowth 0.200000
grossMargins 0.762670
operatingMargins 0.246380
trailingEps 81.130000
forwardEps 99.400000

Positive earnings and revenue growth for Ajanta Pharma Limited suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
With positive gross and operating margins, Ajanta Pharma Limited demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
With AJANTPHARM's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in AJANTPHARM's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

AJANTPHARM's price projections have steadily risen over time, pointing to increasing optimism about the company's prospects. This upward revision suggests that analysts expect AJANTPHARM to continue delivering solid performance in the future.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


5 AJANTPHARM sales were executed, with market price at 2600.4.No sell transactions took place in the period under consideration.The trend of more buys compared to sells around Ajanta Pharma Limited's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


The analysts' recent buy bias for AJANTPHARM indicates strong confidence in the stock's future performance. This could encourage more investors to view AJANTPHARM as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.